NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will be featuring its i-LidTM Cleanser with Neutrox™ for the first time at the International Vision Expo & Conference.
The Vision Expo & Conference is the world’s most important ophthalmic gathering, covering everything from the latest medical information to trends in eyewear fashion. This year, the Vision Expo West meeting will be held in Las Vegas, September 17-20.
NovaBay will be presenting i-Lid Cleanser at its Expo booth (Booth #MS2056 ). In addition, Dr. Arthur Epstein, Director of the Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care, will share his successful experiences using i-Lid Cleanser for such conditions as blepharitis and dry eye syndrome with the nation’s leading eye doctors on September 18 in the Venetian Hotel.
Dr. Epstein’s presentation will be available by contacting NovaBay’s Product Manager, Ameer Mohit.
As Dr. Epstein and NovaBay representatives at the company’s booth will explain, i-Lid Cleanser is the only eye care product to contain Neutrox—pure form of hypochlorous acid (HOCl) produced by NovaBay’s proprietary and patented manufacturing process. Neutrox-containing products have been cleared by the Food & Drug Administration to clean skin and wounds. Labs tests show that Neutrox, identical to a naturally occurring substance produced by white blood cells as a first line of defense against microbial invaders, has potent antimicrobial activity, yet is non-toxic to mammalian cells. Moreover, Neutrox also neutralizes bacterial toxins and breaks up biofilms.
Those properties make i-Lid Cleanser ideal for the management of common eye conditions, such as blepharitis, where Staphylococci bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up. Patients who’ve had blepharitis for years—along with their doctors—report that i-Lid has finally brought relief from the often-painful and potentially sight-threatening condition. As Dr. Epstein will describe, i-Lid Cleanser also has been effective in dry eye syndrome, because it removes both the bacteria and the bacterial toxins that cause the meibomian glands to be obstructed by thick waxy secretions, leading to the syndrome.
In addition, doctors are using i-Lid Cleanser for pre and post surgery lid and lash hygiene. And because Neutrox is not a traditional antibiotic or steroid, there are no risks of bacterial resistance or side effects.
“We’re looking forward to Vision Expo West because we have a great story to tell,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “Once doctors see the results from using i-Lid Cleanser, we believe they will quickly realize that it offers a major improvement in the standard of care.”
This release contains forward-looking statements and opinions regarding the commercial potential of i-Lid Cleanser, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the risk that potential customers will not perceive the benefits of i-Lid Cleanser to be the same as NovaBay believes. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For Investor Inquiries, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson